Avenue therapeutics reports full year 2023 financial results and recent corporate highlights

- enrollment completed in phase 1b/2a clinical trial of aj201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 -

ATXI Ratings Summary

ATXI Quant Ranking